mAbxience
Biosimilar developer, Spain. 2 development products across 2 molecules: bevacizumab, denosumab.
First approval in the Atlas: Mar 2021, Alymsys, bevacizumab (EMA)
FDAproducts approved2
EMAproducts approved2
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Alymsys / Oyavas MB02 | Apr 2022 | Mar 2021 | · | · | · | · |
| Denosumab | Boncresa / Oziltus / Denbrayce / Izamby MB09 | Dec 2025 | Jun 2025 | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMAMar 2021Alymsys, bevacizumab
- EMAMar 2021Oyavas, bevacizumab
- FDAApr 2022Alymsys, bevacizumab
- EMAJun 2025Denbrayce, denosumab
- EMAJun 2025Enwylma, denosumab
- EMAJun 2025Izamby, denosumab
- EMAJun 2025Zadenvi, denosumab
- FDADec 2025Boncresa, denosumab
- FDADec 2025Oziltus, denosumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.